Figure 2.
Cumulative incidence of relapse stratified according to CMV reactivation and grades 2 to 4 acute GVHD. The unadjusted cumulative incidence of relapse in patients with AML (A) and ALL (B). The landmark point was set at day 65.
Cumulative incidence of relapse stratified according to CMV reactivation and grades 2 to 4 acute GVHD. The unadjusted cumulative incidence of relapse in patients with AML (A) and ALL (B). The landmark point was set at day 65.
